Type of sample | Characteristics | Median (range) | No. (%) |
---|---|---|---|
MLL-AF4 (N = 7) | Age at diagnosis, years | 1 (0.25–7) |  |
Sex | Â | Â | |
 Male |  | 4 (57.1) | |
 Female |  | 3 (42.9) | |
Immunophenotype | Â | Â | |
 B |  | 7 (100) | |
 T |  | 0 (0) | |
WBC count, × 109/L | 89 (18.29–173) |  | |
Risk group | Â | Â | |
 H |  | 4 (57.1) | |
 M |  | 0 (0) | |
 S |  | 0 (0) | |
 N/A |  | 3 (42.9) | |
MLL-other fusion type (N = 15) | Age at diagnosis, years | 4 (0.33–13) |  |
Sex | Â | Â | |
 Male |  | 11 (73.4) | |
 Female |  | 4 (26.6) | |
Immunophenotype | Â | Â | |
 B |  | 10 (66.7) | |
 T |  | 5 (33.3) | |
Fusion gene | Â | Â | |
 MLL-AF9 |  | 1 (6.7) | |
 MLL-ENL |  | 2 (13.3) | |
 MLL-AF10 |  | 1 (6.7) | |
 N/A |  | 11 (73.3) | |
WBC count, × 109/L | 72 (4.63–370) |  | |
Risk group | Â | Â | |
 H |  | 9 (60) | |
 M |  | 3 (20) | |
 S |  | 1 (6.7) | |
 N/A |  | 2 (13.3) | |
MLL-wt (N = 30) | Age at diagnosis, years | 8 (1–13) |  |
Sex | Â | Â | |
 Male |  | 19 (63.3) | |
 Female |  | 11 (36.7) | |
Immunophenotype | Â | Â | |
 B |  | 12 (40.0) | |
 T |  | 12 (40.0) | |
 N/A |  | 6 (20.0) | |
WBC count, × 109/L | 31 (2–632.47) |  | |
Risk group | Â | Â | |
 H |  | 7 (23.3) | |
 M |  | 12 (40) | |
 S |  | 5 (16.7) | |
 N/A |  | 6 (20) | |
Normal (N = 16) |  |  | 16 (100) |